Replimune Group
Replimune Group is an emerging class of Cancer Therapeutics company that exploits the ability of viruses to selectively replicate in and kill tumors while at the same time inducing a potent, patient specific, anti tumor immune response. The headquarters is in USA.
Replimune Group Annual Net loss for year ending Mar-2023 was -174 million USD.
Replimune Group Annual Net loss for year ending Mar-2022 was -118 million USD.
As on 2023, Replimune Group has 284 employees.